Why Is Eton Pharmaceuticals (ETON) Stock Plunging On Monday?

by Vandana Singh, Benzinga Editor

August 9, 2021 12:29 PM | 1 min read

According to an SEC filing, the FDA action date for Eton Pharmaceuticals Inc's ETON antiepileptic topiramate oral solution has been delayed three months to November 6.
An FDA decision was expected on Friday.
However, Eton said that privately held Azurity Pharmaceuticals submitted a recent amendment to the drug application.
Topiramate is one of three neurology candidates Azurity purchased from Eton in February.
If approved, Eton is entitled to a $5M milestone payment and a royalty on sales.
Eton suffered a setback in late May when FDA declined to approve the Company's dehydrated alcohol injection for methanol poisoning.
Price Action: ETON stock is down 16.4% at $4.91 on the last check Monday.
Related content: Benzinga's Full FDA Calendar.